Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioventus (BVS) Non-Current Debt (2020 - 2025)

Bioventus' Non-Current Debt history spans 6 years, with the latest figure at $279.0 million for Q4 2025.

  • For Q4 2025, Non-Current Debt fell 9.52% year-over-year to $279.0 million; the TTM value through Dec 2025 reached $279.0 million, down 9.52%, while the annual FY2025 figure was $279.0 million, 9.52% down from the prior year.
  • Non-Current Debt reached $279.0 million in Q4 2025 per BVS's latest filing, down from $311.3 million in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $404.3 million in Q2 2023 to a low of $162.4 million in Q4 2021.
  • Average Non-Current Debt over 5 years is $319.3 million, with a median of $344.9 million recorded in 2024.
  • Peak YoY movement for Non-Current Debt: surged 142.0% in 2022, then fell 16.0% in 2024.
  • A 5-year view of Non-Current Debt shows it stood at $339.6 million in 2021, then rose by 13.36% to $385.0 million in 2022, then fell by 4.68% to $367.0 million in 2023, then dropped by 16.0% to $308.3 million in 2024, then dropped by 9.52% to $279.0 million in 2025.
  • Per Business Quant, the three most recent readings for BVS's Non-Current Debt are $279.0 million (Q4 2025), $311.3 million (Q3 2025), and $297.9 million (Q2 2025).